BTIG lowered the firm’s price target on NeoGenomics to $21 from $23 and keeps a Buy rating on the shares. The company reported a “solid” Q1 earnings beat, but the post-earnings decline is an “over-reaction” to the management’s commentary that they’re evaluating M&A, which the market interpreted to require dilutive financing, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEO: